Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission.
Three courses of intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection were administered to 31 stage II-IV ovarian carcinoma patients who were clinically in complete remission after completion of postoperative cisplatin-based combination chemotherapy. The 5-year survival rate was 60.4% and the median progression-free interval 35 months. Among 25 patients who underwent second-look laparotomy, the survival and the duration of the progression-free interval were significantly better in those with a pathologically confirmed complete response. Short-term intraperitoneal cisplatin chemotherapy should be considered for consolidation of treatment in ovarian carcinoma patients who are clinically in complete remission.
Menczer
J
J
Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
Ben-Baruch
G
G
Rizel
S
S
Brenner
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011182:Postoperative Care; D012074:Remission Induction; D015996:Survival Rate; D013885:Thiosulfates / Q000627:therapeutic use
D013885:Thiosulfates; D002945:Cisplatin